Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Inclusion Criteria • Diagnosis of a confirmed hematological malignancy that has relapsed or is at high risk for relapsing, including any of the following: Acute myeloid leukemia (AML) meeting any of the following criteria: Antecedent hematologic disorder Therapy related Primary induction failure In first complete remission (CR1) with poor-risk cytogenetics, as defined by the following: del(5q)/-5 del(7q)/-7 abn(3q) t(6;9) del(20q) del(17p) +13 Complex karyotype t(9;22) = 11q23 rearrangement In second complete remission (CR2) or greater Acute lymphoblastic leukemia meeting any of the following criteria: In CR1 with WBC \> 50,000/mm³ at diagnosis In CR1 with poor-risk cytogenetics (i.e., t\[9;22\], t\[1;19\], t\[4;11\]) AND meets at least 1 of the following criteria: 19-75 years of age AND received prior high-dose chemotherapy, total-body irradiation (TBI), or a radiation dose that precludes administration of 12 Gy of TBI = 50-75 years of age = 19-75 years of age with hematopoietic stem cell transplantation (HSCT) comorbidity index ≥ 3 CNS or testicular involvement at diagnosis No CR within 4 weeks of initial treatment Primary induction failure In CR2 or greater Myelodysplastic syndromes meeting the following criteria: Intermediate-2 or high-risk category as determined by International Prognostic Scoring System Not considered a candidate for intensive or standard chemotherapy or HSCT Chronic myelogenous leukemia meeting any of the following criteria: First chronic …